Brain metastases from colorectal carcinoma: Prognostic factors and outcome

Minkyu Jung, Joong Bae Ahn, Jong Hee Chang, Chang-Ok Suh, Soojung Hong, Jae Kyung Roh, Sang Joon Shin, SunYoung Rha

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Brain metastases from colorectal carcinoma (CRC) are rare. The objectives of this study are to assess the natural history, outcome, and possible prognostic factors in CRC patients with brain metastases. Between 1995 and 2008, 8,732 patients with CRC were treated at Yonsei University Health System. Brain metastases were found in 1.4% of these patients. Retrospective review and statistical analysis of these 126 patients were performed. Median time from diagnosis of metastatic CRC (mCRC) to brain metastases was 9.0 months (range 0-85 months), and 14 patients (11.1%) had brain involvement as their initial presentation. Among the 126 patients, 91.3% had other systemic metastases; the most common extracranial metastatic site was lung (72.2%). Median follow-up duration was 6.1 months (range 0.1-90.3 months), and median survival after diagnosis of brain metastases was 5.4 months [95% confidence interval (CI) 3.9-6.9 months]. Median survival time after diagnosis of brain metastases was 1.5 months for patients who received only steroids (15.9%), 4.0 months for those who received whole-brain radiation therapy (37.5%), 9.5 months for those who received gamma-knife surgery (GKS) (32.5%), and 11.5 months for those who underwent surgery (20%) (P < 0.001). On multivariate analysis, recursive partitioning analysis (RPA) class and amount of chemotherapy before brain metastasis were independent prognostic factors for survival. Overall prognosis of patients with brain metastases from CRC is poor. Nevertheless, patients with low RPA class, or those with previous less chemotherapy showed good prognosis, indicating that proper treatment may result in improved survival time.

Original languageEnglish
Pages (from-to)49-55
Number of pages7
JournalJournal of Neuro-Oncology
Volume101
Issue number1
DOIs
Publication statusPublished - 2011 Jan 1

Fingerprint

Colorectal Neoplasms
Neoplasm Metastasis
Brain
Survival
Drug Therapy
Natural History
Radiotherapy
Multivariate Analysis
Steroids
Confidence Intervals
Lung
Health

All Science Journal Classification (ASJC) codes

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Jung, Minkyu ; Ahn, Joong Bae ; Chang, Jong Hee ; Suh, Chang-Ok ; Hong, Soojung ; Roh, Jae Kyung ; Shin, Sang Joon ; Rha, SunYoung. / Brain metastases from colorectal carcinoma : Prognostic factors and outcome. In: Journal of Neuro-Oncology. 2011 ; Vol. 101, No. 1. pp. 49-55.
@article{0ada74156cac41dabd836c963557477f,
title = "Brain metastases from colorectal carcinoma: Prognostic factors and outcome",
abstract = "Brain metastases from colorectal carcinoma (CRC) are rare. The objectives of this study are to assess the natural history, outcome, and possible prognostic factors in CRC patients with brain metastases. Between 1995 and 2008, 8,732 patients with CRC were treated at Yonsei University Health System. Brain metastases were found in 1.4{\%} of these patients. Retrospective review and statistical analysis of these 126 patients were performed. Median time from diagnosis of metastatic CRC (mCRC) to brain metastases was 9.0 months (range 0-85 months), and 14 patients (11.1{\%}) had brain involvement as their initial presentation. Among the 126 patients, 91.3{\%} had other systemic metastases; the most common extracranial metastatic site was lung (72.2{\%}). Median follow-up duration was 6.1 months (range 0.1-90.3 months), and median survival after diagnosis of brain metastases was 5.4 months [95{\%} confidence interval (CI) 3.9-6.9 months]. Median survival time after diagnosis of brain metastases was 1.5 months for patients who received only steroids (15.9{\%}), 4.0 months for those who received whole-brain radiation therapy (37.5{\%}), 9.5 months for those who received gamma-knife surgery (GKS) (32.5{\%}), and 11.5 months for those who underwent surgery (20{\%}) (P < 0.001). On multivariate analysis, recursive partitioning analysis (RPA) class and amount of chemotherapy before brain metastasis were independent prognostic factors for survival. Overall prognosis of patients with brain metastases from CRC is poor. Nevertheless, patients with low RPA class, or those with previous less chemotherapy showed good prognosis, indicating that proper treatment may result in improved survival time.",
author = "Minkyu Jung and Ahn, {Joong Bae} and Chang, {Jong Hee} and Chang-Ok Suh and Soojung Hong and Roh, {Jae Kyung} and Shin, {Sang Joon} and SunYoung Rha",
year = "2011",
month = "1",
day = "1",
doi = "10.1007/s11060-010-0214-9",
language = "English",
volume = "101",
pages = "49--55",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "1",

}

Brain metastases from colorectal carcinoma : Prognostic factors and outcome. / Jung, Minkyu; Ahn, Joong Bae; Chang, Jong Hee; Suh, Chang-Ok; Hong, Soojung; Roh, Jae Kyung; Shin, Sang Joon; Rha, SunYoung.

In: Journal of Neuro-Oncology, Vol. 101, No. 1, 01.01.2011, p. 49-55.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Brain metastases from colorectal carcinoma

T2 - Prognostic factors and outcome

AU - Jung, Minkyu

AU - Ahn, Joong Bae

AU - Chang, Jong Hee

AU - Suh, Chang-Ok

AU - Hong, Soojung

AU - Roh, Jae Kyung

AU - Shin, Sang Joon

AU - Rha, SunYoung

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Brain metastases from colorectal carcinoma (CRC) are rare. The objectives of this study are to assess the natural history, outcome, and possible prognostic factors in CRC patients with brain metastases. Between 1995 and 2008, 8,732 patients with CRC were treated at Yonsei University Health System. Brain metastases were found in 1.4% of these patients. Retrospective review and statistical analysis of these 126 patients were performed. Median time from diagnosis of metastatic CRC (mCRC) to brain metastases was 9.0 months (range 0-85 months), and 14 patients (11.1%) had brain involvement as their initial presentation. Among the 126 patients, 91.3% had other systemic metastases; the most common extracranial metastatic site was lung (72.2%). Median follow-up duration was 6.1 months (range 0.1-90.3 months), and median survival after diagnosis of brain metastases was 5.4 months [95% confidence interval (CI) 3.9-6.9 months]. Median survival time after diagnosis of brain metastases was 1.5 months for patients who received only steroids (15.9%), 4.0 months for those who received whole-brain radiation therapy (37.5%), 9.5 months for those who received gamma-knife surgery (GKS) (32.5%), and 11.5 months for those who underwent surgery (20%) (P < 0.001). On multivariate analysis, recursive partitioning analysis (RPA) class and amount of chemotherapy before brain metastasis were independent prognostic factors for survival. Overall prognosis of patients with brain metastases from CRC is poor. Nevertheless, patients with low RPA class, or those with previous less chemotherapy showed good prognosis, indicating that proper treatment may result in improved survival time.

AB - Brain metastases from colorectal carcinoma (CRC) are rare. The objectives of this study are to assess the natural history, outcome, and possible prognostic factors in CRC patients with brain metastases. Between 1995 and 2008, 8,732 patients with CRC were treated at Yonsei University Health System. Brain metastases were found in 1.4% of these patients. Retrospective review and statistical analysis of these 126 patients were performed. Median time from diagnosis of metastatic CRC (mCRC) to brain metastases was 9.0 months (range 0-85 months), and 14 patients (11.1%) had brain involvement as their initial presentation. Among the 126 patients, 91.3% had other systemic metastases; the most common extracranial metastatic site was lung (72.2%). Median follow-up duration was 6.1 months (range 0.1-90.3 months), and median survival after diagnosis of brain metastases was 5.4 months [95% confidence interval (CI) 3.9-6.9 months]. Median survival time after diagnosis of brain metastases was 1.5 months for patients who received only steroids (15.9%), 4.0 months for those who received whole-brain radiation therapy (37.5%), 9.5 months for those who received gamma-knife surgery (GKS) (32.5%), and 11.5 months for those who underwent surgery (20%) (P < 0.001). On multivariate analysis, recursive partitioning analysis (RPA) class and amount of chemotherapy before brain metastasis were independent prognostic factors for survival. Overall prognosis of patients with brain metastases from CRC is poor. Nevertheless, patients with low RPA class, or those with previous less chemotherapy showed good prognosis, indicating that proper treatment may result in improved survival time.

UR - http://www.scopus.com/inward/record.url?scp=78651288960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651288960&partnerID=8YFLogxK

U2 - 10.1007/s11060-010-0214-9

DO - 10.1007/s11060-010-0214-9

M3 - Article

C2 - 20467783

AN - SCOPUS:78651288960

VL - 101

SP - 49

EP - 55

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1

ER -